

**MINUTES
AREA DRUG AND THERAPEUTICS COMMITTEE
WEDNESDAY 20th October @10am
Microsoft Teams Meeting**

In Attendance:

Dr Mehrdad Malekian Ms Linda Johnstone
Dr David Semple Mrs Chrstine Gilmour
Dr Stephanie Dundas Mrs Carol McGoff
Mrs Katrina Maroni Mrs Emma Harris
Mrs Gail Richardson

Action

Kirsty Macfarlane in attendance Lesley Dewar in attendance for item 7

2021/157	1.	<p><u>Apologies for Absence</u> Mr George Lindsay, Mr Iain Hathorn, Mrs Karen Patterson, Mr Bill Angus, Mr John Milne, Dr Tyra Smyth, Ms Ann Auld, Mrs Penny Brankin</p>	
2021/158	2.	<p><u>Declaration of Interest</u> There were no declarations of interest</p>	
2021/159	3.	<p><u>Matters arising not covered elsewhere on the agenda</u></p> <p>a. <u>Ratification of minutes of meeting 15th September 2021</u> The minute was accepted as an accurate record and can now be published.</p> <p>b. <u>Dapaqliflozin in Heart Failure (Non Diabetic)</u> Deferred until November meeting.</p> <p>c. <u>Guidance on the review of patients on intramuscular vitamin B12 (hydroxocobalamin) injections and identifying those in whom this may be stopped</u> This item was noted as the final version.</p> <p>d. <u>Remdesivir – coordination with Clinical Bronze</u> ADTC had previously agreed that a link to any national covid guidance within the Clinical Guideline site would be progressed especially as much of this guidance is changing frequently. There was further discussion as national guidance does not consider the local logistics and there is then no quick reference or appendix to the national guidance. It was agreed that the Clinical Bronze group will be required to approve this and Dr Malekian has already signed the Unlicensed Medicine Form C. It was noted that communication and links to all the various groups could be improved. SD suggested adding an appendix to the national guidance detailing specific additional local guidance but the Clinical Bronze group would need to prepare this.</p>	<p>ALL</p> <p>MM</p> <p>EH</p> <p>CG</p>

	<p>MM to discuss with Dr Keaney how to improve communication channels and ensure any clinical guidance being developed has input from all the clinical specialities prior to going to the Bronze group.</p> <p>e. <u>LMWH - Extremes of body weight</u> Deferred until the November meeting.</p> <p>f. <u>Measuring Renal Function to determine drug doses</u> Discussion around the use of online calculators and that these are required to determine drug doses and in regular use by the pharmacists working on the wards.</p> <p>g. <u>Oxygen Prescribing in Acute Settings</u> This item was not raised at Acute Clinical Governance in October due to a lengthy agenda and is to be raised at the next meeting. MM to raise with Dr Keaney, discussion around the roll out of Patient Trak which would streamline the process of prescribing oxygen on NEWS chart.</p> <p>h. <u>Guideline for Management of infection - Cystic Fibrosis</u> Dr Dundas discussed that this document had been fully discussed and approved by the Antimicrobial Committee (AMC) – approved.</p> <p>i. <u>Steroid Emergency Cards</u> HIS have now issued these cards to all hospitals. Pharmacy cannot distribute these cards to all patients on steroids as they do not have that intelligence. Ideally they would be issued following an outpatient consultation. They will cover a wide group of patients with different exposures / different specialities and cover new and existing patients. The preference is to use national correspondence and guidance and Christine will discuss and develop some options – all members asked to contribute.</p> <p>j. <u>Guidance on Production of Guidelines</u> Members were asked to comment via email to MM on the document circulated, with the final version to be tabled at the November meeting. Clinical Guidelines Group has suggested developing a guideline template which Kirsty Macfarlane is pulling together and will share at a later meeting.</p>	<p>KP</p> <p>CG</p> <p>GR</p> <p>CG</p> <p>ALL</p>
2021/160 4.	<p><u>SMC</u></p> <p><u>FULL SUBMISSIONS</u></p> <p>Selpercatinib (Retsevmo®) SMC2371 This was noted.</p> <p>Osimertinib (Tagrisso®) SMC2383 This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN) for comments / clinical protocol.</p>	

NON SUBMISSIONS

Asfotase alfa (Strensiq®) SMC2433

This was noted.

Durvalumab (Imfinzi®) SMC2434

This was noted.

Olaparib (Lynparza®) SMC2435

This was noted.

Olaparib (Lynparza®) SMC2436

This was noted.

Sebelipase alfa (Kanuma®) SMC2437

This was noted.

AMENDED ADVICE

Liraglutide (Saxenda®) SMC2378

This was noted.

UPDATE ON THE INTERIM ASSESSMENT APPROACH IN RESPONSE TO COVID-19

This is a pragmatic approach to minimise delay in patient access as a result of the COVID-19 pandemic. Following review by the SMC executive, SMC advice for four submissions noted below will be published on the SMC website on Monday 08 November 2021.

FULL SUBMISSIONS

Atezolizumab (Tecentriq®) SMC2379

This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN) for comments / clinical protocol.

Pembrolizumab (Keytruda®) SMC2380

This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN) for comments / clinical protocol.

ABBREVIATED SUBMISSIONS

Bimekizumab (Bimzelx®) SMC2410

This was noted and will be referred to Dermatology.

Ponesimod (Ponvory®) SMC2384

This was noted.

ULTRA ORPHAN (UO)

The following medicine was validated as UO:

Avalglucosidase alfa (Nexviadyme®) for long-term enzyme

	<p>replacement therapy for the treatment of patients with Pompe disease (acid α-glucosidase deficiency). This was noted.</p>	
2021/161	<p>5. <u>SMC follow up</u></p> <p>Mrs Maroni talked the committee through the SMC follow up which had been previously circulated. Feedback / clinical protocols for several items are expected in due course.</p>	KM
2021/162	<p>6. <u>Lanarkshire Formulary</u></p> <p>Mrs McGoff raised three amendments. The first is the addition of upadacitinib following recent ratification of the clinical protocol relating to SMC advice 2315 and 2361. This was approved. Following on from the previous discussion at the October ADTC, Mrs McGoff discussed the amended S2 formulary category definition, this was agreed by the committee. Finally reference to Tissue Viability Service emails, for submission of a patient referral, are to be removed as no longer in use. A link to the department's FirstPort page will be added to the wound management chapter. This link enables staff to access the service specification document, eReferral form and submission steps.</p>	CMcG
2021/163	<p>7. <u>Clinical Protocols</u></p> <p>1. <u>Paediatric Aminoglycoside Antibiotic Leaflets</u></p> <p>These have already been tabled, discussed and agreed at AMC. Approved and to go on to the Clinical Guideline site linking to Paediatric Medicines Policies.</p> <p>2. <u>High Dose Antipsychotic Treatment Guidelines</u></p> <p>Lesley Dewar attended for this item and updated the committee on the updated version of the treatment guidelines. Lesley highlighted the new sections around consent and regulation. There is no change to sections on roles and responsibilities and all hyperlinks will be updated. Content approved and once links updated this will be hosted on the Clinical Guideline site.</p> <p>3. <u>Filgotinib Protocol</u></p> <p>This medicine will be supplied via Homecare and was approved. Comment that within the GP information the indication for treatment was missing. There was then a useful discussion on the Clinical Guideline site and where this type of guidance should sit within a speciality tab or not. MM raised that the old guideline site will be switched off in the near future and should Homecare guidance sit on the new site or within a Homecare section. The committee were asked to consider should there be a medicine guidance tab created and to email MM with any further suggestions. SD raised that rapid access to</p>	<p>GR</p> <p>LD/LT</p>

	<p>guidance within receiving units for emergency treatment is often required and should there be an Emergency treatment / emergency care section.</p> <p>4. <u>Peripheral Noradrenaline Infusion</u></p> <p>This guidance was discussed and several comments raised</p> <ul style="list-style-type: none"> - Why is the document specific to Monklands and not NHSL? - Concern re difference in dosing 20mls/hr and 13mls/hr both stated. - mcg – not in full – micrograms - MM to ask for clarification on the points raised. 	
2021/164	<p>8. <u>ADTC Bulletin</u></p> <p>This was noted.</p>	KM
2021/165	<p>9. <u>Unlicensed Medicines</u></p> <p>NIL to report.</p>	
2021/166	<p>10. <u>Patient Group Directions</u></p> <p>1. <u>Bridging Contraception – Community Pharmacy</u></p> <p>For Noting – MM to check with George Lindsay around any actions.</p>	GL
2021/167	<p>11. <u>Medication and Clinical risk in Lanarkshire</u> https://www.gov.uk/drug-safety-update</p> <p>This was noted.</p>	
2021/168	<p>12. <u>Regional Cancer Advisory Network</u></p> <p>Nil to report.</p>	
2021/169	<p>13. <u>Patient Safety Alerts</u></p> <p>Nil to report.</p>	
2021/170	<p>14. <u>Lay member related items</u></p> <p>Nil</p>	

<p>2021/171 15.</p>	<p><u>Correspondence</u></p> <p><u>ADTCC Correspondence</u></p> <p>1. <u>MHRA Early Access to Medicines Scheme: Expiry of scheme for tepotinib in the treatment of advanced non-small cell lung cancer (NSCLC) EAMS 11648/0004</u></p> <p>This was noted.</p> <p>2. <u>FW: Scottish Medicines Consortium (SMC) advice on buprenorphine medicines when used in opioid substitution treatment (OST)</u></p> <p>This was noted.</p>	
<p>2021/172 16.</p>	<p><u>Pharmacy & NMAHP Prescribing Governance</u></p> <p>Nil to report.</p>	
<p>2021/173 17.</p>	<p><u>AOCB</u></p> <ul style="list-style-type: none"> - KM raised that the Joint Adult Formulary website migration is ongoing but cannot have any tables embedded within the website. KM/CMcG will reconfigure without using tables but still give clear guidance. The diabetes treatment summary table will be replaced with a link to the SIGN treatment algorithm. - DS raised the Clinical Guidelines site and exactly how the hyperlinks will work. MM agreed to share the infographics on the guideline site usage. KM confirmed that the new formulary platform has improved functionality and the reports generated can show when links are no longer active. 	
<p>2021/174 18.</p>	<p><u>Date of next meeting</u></p> <p>Wednesday 17th November 2021 10am @ Microsoft Teams</p>	